Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Gastro-enteropancreatic neuroendocrine tumor 4Carcinoma, Hepatocellular 2Carcinoid Tumor 2Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Gastrointestinal Neoplasms 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 130Nivolumab 87atezolizumab 80pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × lanreotide × Gastrointestinal × Clear all
NCT02973204 2021-04-28

Circulating Tumor Cells and Tumor DNA in HCC and NET

University of Aarhus

Completed
167 enrolled
EndocrineGastrointestinalNET

Carcinoma, Hepatocellular, Neoplastic Cells, Circulating, Neuroendocrine Tumors

NCT00495846 2009-08-17

SS-HCC

Federico II University

Phase 2/3 Completed
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡